Biotechnology firm Cure Genetics, which is engaged in the development of life-saving transformative medicines and molecular diagnostics using gene editing technologies, has raised $17m Series A financing, led by Qiming Venture Partners.
Additional investors included CTS Capital and Ascendin Investment. The company intends to use the proceeds to further optimize its gene editing and delivery platform, to sponsor IND application and clinical trials, and to develop its diverse pipelines.
CureGenetics co-founder and CEO Yuanyuan Xu said: “Being a unique player of this field, we have recruited top-tier scientists and business partners to develop and promote our proprietary technology platform.
“We are delighted by the votes of confidence from all the investors, and this financing puts us in strong position to accelerate the development of multiple pipelines, and to keep investing in these game-changing technologies.”
Qiming Venture Partners managing partner Nisa Leung said: “We are very pleased to support the growth of CureGenetics. We believe that the outstanding technology platform and the top-class talents will continue to help advance the company as well as the gene editing research.”
CTS Capital founding and managing partner Song Zhang said: “Gene editing has great potential in clinical applications and commercialization. We are confident that CureGenetics, as one of the most competitive players in this field, will lead the cutting-edge industry worldwide.”
Source: Company Press Release